Gossamer Bio Inc (GOSS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $67.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gossamer Bio Inc (GOSS) Competitors
The companies most similar to Gossamer Bio are ImageneBio (IMA), Coherus BioSciences (CHRS) and Genelux Corporation Common Stock (GNLX). By market cap, Gossamer Bio ranks 6th of the 13 companies on this page; Foghorn Therapeutics (FHTX) is the largest at $124.12M.
Peer Comparison
GOSS's revenue growth of 189.1% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Gossamer Bio (GOSS) | $67.10M | N/A | 0.9x | -159.5% | 147.4% | 189.1% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Genelux Corporation Common Stock (GNLX) | $84.38M | N/A | N/A | 0.0% | N/A | -95.3% | 0.00% |
| Gain Therapeutics Inc (GANX) | $46.31M | N/A | N/A | 0.0% | -170.5% | -100.0% | 0.00% |
| Cardiff Oncology Inc (CRDF) | $56.49M | N/A | 115.5x | 0.0% | N/A | -14.1% | 0.00% |
| iBio, Inc. Common Stock (IBIO) | $51.55M | N/A | 735.4x | 0.0% | N/A | 975.0% | 0.00% |
| Connect Biopharma Holdings Ltd (CNTB) | $42.65M | N/A | 13.6x | 0.0% | N/A | 5667.0% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oncolytics Biotech Inc (ONCY) | $48.51M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biomea Fusion Inc (BMEA) | $42.31M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Foghorn Therapeutics Inc (FHTX) | $124.12M | 40.1x | 1.1x | 8.4% | N/A | 925.0% | 0.00% |
| Seer Inc (SEER) | $87.63M | N/A | 5.8x | 0.0% | N/A | -3.4% | 0.00% |
| Peer median | $54.02M | 40.1x | 13.6x | 0.0% | -157.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Gossamer Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Genelux Corporation Common Stock (GNLX) | Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering... | GNLX competitors |
| Gain Therapeutics Inc (GANX) | Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. | GANX competitors |
| Cardiff Oncology Inc (CRDF) | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. | CRDF competitors |
| iBio, Inc. Common Stock (IBIO) | iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. | IBIO competitors |
| Connect Biopharma Holdings Ltd (CNTB) | Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators... | CNTB competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Oncolytics Biotech Inc (ONCY) | Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. | ONCY competitors |
| Biomea Fusion Inc (BMEA) | Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat... | BMEA competitors |
| Foghorn Therapeutics Inc (FHTX) | Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within... | FHTX competitors |
| Seer Inc (SEER) | Seer, Inc., a life sciences company, is dedicated to developing and marketing products for researchers to unlock biological information. | SEER competitors |
Frequently Asked Questions About GOSS
Who are Gossamer Bio's main competitors?
The companies most similar to Gossamer Bio include ImageneBio (IMA), Coherus BioSciences (CHRS), Genelux Corporation Common Stock (GNLX), Gain Therapeutics (GANX) and Cardiff Oncology (CRDF), listed from the closest match.
Who is Gossamer Bio's biggest competitor?
Foghorn Therapeutics (FHTX) is the largest of the similar companies at $124.12M; ImageneBio (IMA) is the closest match by business profile, size, sector and industry.
How does GOSS stock compare with its competitors?
GOSS' P/S is 0.9x against a peer median of 13.6x; its net margin is -159.5% against a peer median of 0.0%.
Which of Gossamer Bio's competitors pays a higher dividend?
Gossamer Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Gossamer Bio bigger than its competitors?
No. Gossamer Bio is 6th by market cap among the 13 companies on this page; the largest is Foghorn Therapeutics (FHTX) at $124.12M.
GOSS pages: Overview, Earnings, Forecast, Financials, Competitors